- Home
- SAIH vs MEIP Comparison
SAIH vs MEIP Comparison
Compare SAIH & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- MEIP
- Stock Information
- Founded
- SAIH 2019
- MEIP 2000
- Country
- SAIH Singapore
- MEIP United States
- Employees
- SAIH N/A
- MEIP N/A
- Industry
- SAIH
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- SAIH
- MEIP Health Care
- Exchange
- SAIH NYSE
- MEIP Nasdaq
- Market Cap
- SAIH 12.3M
- MEIP 13.3M
- IPO Year
- SAIH N/A
- MEIP 2003
- Fundamental
- Price
- SAIH $7.20
- MEIP $2.80
- Analyst Decision
- SAIH
- MEIP Hold
- Analyst Count
- SAIH 0
- MEIP 1
- Target Price
- SAIH N/A
- MEIP N/A
- AVG Volume (30 Days)
- SAIH 20.2K
- MEIP 13.3K
- Earning Date
- SAIH 04-28-2025
- MEIP 05-13-2025
- Dividend Yield
- SAIH N/A
- MEIP N/A
- EPS Growth
- SAIH N/A
- MEIP N/A
- EPS
- SAIH N/A
- MEIP N/A
- Revenue
- SAIH $5,543,000.00
- MEIP N/A
- Revenue This Year
- SAIH N/A
- MEIP N/A
- Revenue Next Year
- SAIH N/A
- MEIP N/A
- P/E Ratio
- SAIH N/A
- MEIP N/A
- Revenue Growth
- SAIH N/A
- MEIP 33.76
- 52 Week Low
- SAIH $3.00
- MEIP $1.46
- 52 Week High
- SAIH $26.98
- MEIP $4.10
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- MEIP 78.43
- Support Level
- SAIH N/A
- MEIP $2.21
- Resistance Level
- SAIH N/A
- MEIP $2.95
- Average True Range (ATR)
- SAIH 0.00
- MEIP 0.15
- MACD
- SAIH 0.00
- MEIP 0.05
- Stochastic Oscillator
- SAIH 0.00
- MEIP 81.48
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations. The Company has four reportable segments: equipment sales, hosting, mining pool business, and mining.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.